|
 
 |
| ERRATUM |
|
| Year : 2017 | Volume
: 16
| Issue : 2 | Page : 131 |
|
Erratum: Assessment of some synthesized novel 9-substituted tetrahydroacridine derivatives in diabetic disease management in rats
| Date of Web Publication | 8-Sep-2017 |
Correspondence Address:
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/epj.epj_27_17
How to cite this article:
. Erratum: Assessment of some synthesized novel 9-substituted tetrahydroacridine derivatives in diabetic disease management in rats. Egypt Pharmaceut J 2017;16:131 |
How to cite this URL:
. Erratum: Assessment of some synthesized novel 9-substituted tetrahydroacridine derivatives in diabetic disease management in rats. Egypt Pharmaceut J [serial online] 2017 [cited 2021 Jun 18];16:131. Available from: http://www.epj.eg.net/text.asp?2017/16/2/131/214207 |
In the article titled “Assessment of some synthesized novel 9-substituted tetrahydroacridine derivatives in diabetic disease management in rats” published in pages 53–61, issue 1, vol. 16 of Egyptian Pharmaceutical Journal[1], the sentences “Analysis: for C18H19N3O (283.2); calculated: C: 76.27, H: 6.70, N: 14.83%; found: C: 75.75, H: 6.55, N: 15.32%.” and “Analysis: for C18H19N3O2(309.2) Calcd, C, 70.00; H, 6.14, N, 13.59%, Found, C, 70.15, H, 6.55; N, 13.32%.”under the “Materials and Methods” section are written incorrectly. The correct sentences should read as “Analysis: for C18H20N3 (276.2); calculated: C: 78.26, H: 7.24, N: 15.21%; found: C: 77.66, H: 6.90, N: 14.70%.” and “Analysis for C18H20N3 (276.2) Calcd, C, 78.26, H: 7.24, N: 15.21%; found: C: 77.66, H: 6.90, N: 14.70%.” respectively.
| References | |  |
| 1. | Abdel Megeed RM, Ghanem HZ, Kamel MM, Bakeet MF, Abdel-Hamid AHZ. Assessment of some synthesized novel 9-substituted tetrahydroacridine derivatives in diabetic disease management in rats. Egypt Pharmaceut J 2017;16:53–61.  |
|
